ScreenerHero
UCBUCB SA
EBR · BE · Healthcare · Biotechnology · ucb.com
221.70EUR+1.74%Mkt Cap: 45.95B $P/E: 19.57

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn'…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD

Key Statistics

Company
Market Cap45.95B $
Enterprise Value48.23B $
Revenue (TTM)9.27B $
Gross Profit6.25B $
Net Income (TTM)1.69B $
Revenue/Share48.66 USD
Last Price221.70 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.0K
CountryBE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)19.57
P/E (Forward)15.64
PEG1.32
EV/EBITDA13.28
EV/Revenue5.20
P/S4.87
P/B3.82
EPS (TTM)11.33
EPS (Forward)13.93
52W Range
191.2031% of range289.50
52W High289.50 EUR
52W Low191.20 EUR
Profitability
Gross Margin74.29%
Oper. Margin33.33%
EBITDA Margin39.21%
Profit Margin20.13%
ROE14.34%
ROA8.58%
Growth
Revenue Growth22.50%
Earnings Growth134.80%
Cash Flow & Leverage
Operating CF2.49B $
CapEx (TTM)488.04M $
FCF Margin12.88%
FCF Yield2.60%
Net Debt3.07B $
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.21
Current Ratio1.20
Quick Ratio0.72
Book Value/Sh57.09 EUR
Cash/Share4.018 EUR
Dividends
Fwd Div Rate1.450 EUR
Trail. Div Rate1.450 EUR
Div. Yield0.67%
5Y Avg Yield1.17%
Payout Ratio12.81%
Ex-Div DateMay 4, 2026
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)285.26 EUR
Upside (mean)+28.7%
Target Range208.00 EUR – 340.00 EUR
€208.00+28.7% to mean€340.00
# Analysts19
Ownership
Shares Out.190.66M
Float120.16M
Insiders36.28%
Institutions38.69%
Technical
SMA 50241.72 (-8.3%)
SMA 200248.03 (-10.6%)
Beta0.18
S&P 52W Chg18.16%
Avg Vol (30d)217.34K
Avg Vol (10d)196.28K
Technical Indicators
RSI (14)38.4
MACD-7.1260
MACD Signal-6.7724
MACD Hist.-0.3536
BB Upper252.37 EUR
BB Middle227.67 EUR
BB Lower202.98 EUR
BB Width21.69%
ATR (14)7.039 EUR
Vol Ratio (20d)0.77x